The MarketWatch News Department was not involved in the creation of this content. Certification opens the United Kingdom market for the first FDA-cleared AI platform for prostate MRI interpretation.

One of the most promising advancements is ProstatID, developed by Bot Image Inc. This AI-based technology has demonstrated remarkable success, improving prostate cancer detection rates by over 30% ...

EDINBURGH, Scotland, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Blackford, the pioneering AI platform and solutions provider, and Bot Image today announced a commercial partnership to bring Bot Image’s ...

The U.S. FDA gave Bot Image Inc. a coveted threefer with 510(k) clearance for its Prostatid artificial intelligence (AI) software for detection, diagnosis and monitoring of prostate cancer using both ...

Certification opens the European market for the first FDA-cleared AI platform for prostate MRI interpretation. OMAHA, Neb., Oct. 27, 2025 /PRNewswire/ -- Bot Image, Inc., a leader in AI-powered ...

OMAHA, Neb. and BELGRADE, Maine, May 27, 2025 /PRNewswire/ -- The recent announcement that a former president of the United States developed late-stage prostate cancer is a distressing reminder of the ...